Login to Your Account



‘Alder’ or nothing: biopharma files for $115M IPO

By Marie Powers
Staff Writer

Wednesday, March 19, 2014
financings_resized.jpg

The bulls marched on as Alder Biopharmaceuticals Inc. joined the growing queue of biotechs seeking to prevail on the public markets. The Bothell, Wash.-based company filed a registration statement with the SEC seeking to raise up to $115 million in its initial public offering (IPO) to fund its ongoing clinical program for lead compound ALD403, a monoclonal antibody targeting calcitonin gene-related peptide, or CGRP, to prevent migraine headache. Filing as an emerging growth company, Alder plans to list on the Nasdaq Global Market under the ticker ALDR.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription